CN109419777A - A kind of Enrofloxacin pellet tablet - Google Patents
A kind of Enrofloxacin pellet tablet Download PDFInfo
- Publication number
- CN109419777A CN109419777A CN201710735932.4A CN201710735932A CN109419777A CN 109419777 A CN109419777 A CN 109419777A CN 201710735932 A CN201710735932 A CN 201710735932A CN 109419777 A CN109419777 A CN 109419777A
- Authority
- CN
- China
- Prior art keywords
- parts
- enrofloxacin
- pellet
- pellet tablet
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 34
- 239000008188 pellet Substances 0.000 title claims abstract description 18
- 239000000853 adhesive Substances 0.000 claims abstract description 15
- 230000001070 adhesive effect Effects 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000004088 foaming agent Substances 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920000178 Acrylic resin Polymers 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- -1 hydroxypropyl Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000113 methacrylic resin Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to field of medicaments, are a kind of Enrofloxacin pellet tablet, including following components and each component parts by weight are as follows: 100-300 parts of Enrofloxacin, 10-40 parts of disintegrating agent, 20-60 parts of adhesive, 300-1000 parts of diluent；Pellet particle is made after mixing raw material when preparation, is coated with separation layer in pellet particle surface, is coated with slow release layer again outside separation layer；Product of the present invention take after can rapidly, be evenly distributed on gastrointestinal tract, it is big in gastrointestinal tract distribution area, and as multiple-unit medicine-releasing system, have bioavilability high, rate of releasing drug is uniform, favorable reproducibility, less or the features such as eliminate stimulation of the drug to gastrointestinal tract.
Description
Technical field
The present invention relates to field of medicaments, specifically a kind of Enrofloxacin pellet tablet.
Background technique
Enrofloxacin is also known as Enrofloxacin, is the fluoroquinolones of animal specific, is broad-spectrum antibiotic class drug, can
For treating respiratory tract caused by bacterium and mycoplasma, alimentary canal, urogenital infections and suppurative dermatosis.The medicine
The mechanism of action be selectivity the DNA gyrase for acting on prokaryotes, thus make the synthesis of mRNA and protein lose
Control, blocks the duplication of DNA of bacteria, leads to bacterial death.Enrofloxacin absorbs rapidly after being administered in animal body, reaches stable state
The drug concentration in tissue is higher than the drug concentration in blood plasma afterwards, therefore Enrofloxacin can be used as systemic treatment drug use
It is administered in systemic treatment.Current Enrofloxacin preparation has injection, Enrofloxacin piece and micro-capsule etc., because of animal bacteria
Property infectious disease therapeutic process it is longer, and enrofloxacin injection is in the self-administration of pet clinically inconvenient pet owner
Treatment, therefore there is certain use limitation；Now the Enrofloxacin piece that generally uses mostly because administration number of times frequently caused by blood
Concentration fluctuates too big influence therapeutic effect, and because frequent drug administration increases the risk bitten by pet.Therefore the present invention mentions
Enrofloxacin sustained release tablets have been supplied, administration mode originally twice a day can be reduced to once a day, improve clinical treatment
Effect, and reduce the risk to come to harm.
Patent (CN101190194A, on June 4th, 2008 open) provides a kind of dog cat and is chewed with Enrofloxacin
Piece is mainly made of Enrofloxacin, Aspartame, oral glucose, skimmed milk power, magnesium stearate, starch, dextrin etc., mainly
Advantage is to enhance the palatability of Enrofloxacin, facilitates clinical administration, but is administered and frequently easily causes blood concentration fluctuation mistake
Therapeutic effect when greatly, to clinical treatment is affected.Patent (CN1177300A, on March 25th, 1998 are open)
The preparation method of a kind of Enrofloxacin injection or infusion is provided, is mainly made of Enrofloxacin and multi-hydroxy carboxy acid, this is specially
Benefit have the advantages that easily inject, it is stable, but its not can solve be administered in clinic difficulty problem.Patent (CN 102949365
A, on March 6th, 2013 are open) a kind of pet Enrofloxacin sustained release tablets and preparation method thereof are provided, solve Enrofloxacin to
The problem that medicine frequently easily causes blood concentration fluctuation excessive, but common sustained release tablets bioavilability, efficacy and saferry energy
It is all to be improved.
Summary of the invention
Present invention aim to solve the administration of existing Enrofloxacin piece frequently cause blood concentration fluctuation excessive and
The unstable problem of curative effect provides a kind of convenient drug administration, persistent, the stable Enrofloxacin pellet tablet of curative effect.
A kind of Enrofloxacin pellet tablet of the invention includes following components and each component parts by weight are as follows: Enrofloxacin 100-
300 parts, 10-40 parts of disintegrating agent, 20-60 parts of adhesive, 300-1000 parts of diluent；Be made pellet after raw material being mixed when preparation
Particle is coated with separation layer in pellet particle surface, is coated with slow release layer again outside separation layer.
Heretofore described disintegrating agent is low-substituted hydroxypropyl methylcellulose, sodium carboxymethylcellulose, sodium carboxymethyl starch
In any one or more.
Heretofore described adhesive is water, ethyl alcohol, polyvinylpyrrolidone, any one or more in starch slurry.
Heretofore described diluent is microcrystalline cellulose, starch, mannitol, dextrin, in sucrose any one or it is more
Kind.
By 20-60 parts of adhesive, 10-30 parts of antiplastering aid are constituted heretofore described separation layer；Wherein described adhesive is
Low viscosity hypromellose；The antiplastering aid is any one in talcum powder and silica.
Heretofore described slow release layer is by 100-300 parts of slow-release material, 20-80 parts of plasticiser, 10-40 parts of coatings auxiliary agent
It is formed with 5-30 parts of pore-foaming agent；The slow-release material includes methacrylic resin copolymer, polyacrylic resin, ethyl cellulose
One or more of element and cellulose acetate；The plasticiser includes triethyl citrate；The coatings auxiliary agent is dioxy
Change titanium；The pore-foaming agent is polyethylene glycol.
The invention has the following beneficial effects: the 1, present invention has specific release structures, and it can be extensive after taking, it is evenly distributed
In gastrointestinal tract；2, the present invention has the characteristics that good effect, highly-safe；3, the present invention has convenient drug administration, persistent, curative effect
Stable advantage.
Specific embodiment
Embodiment 1
The present embodiment prescription preparation step:
1, Enrofloxacin 200mg is weighed, carboxymethyl starch receives 40mg, and microcrystalline cellulose 80mg is uniformly mixed spare；
2, it takes appropriate polyvinylpyrrolidone to be dissolved in 75% ethanol solution, makes the mass fraction of polyvinylpyrrolidone
10%, it dissolves intact rear spare as adhesive；
3, hypromellose 12mg is taken, talcum powder 4mg is evenly spread in 10% ethanol solution of 100mg, as separation layer
Coating solution is spare；
4, ethyl cellulose 52mg, triethyl citrate 4mg are taken, titanium dioxide 4mg, 4mg polyethanol 6000 evenly spreads to 10%
It is spare as sustained release coating liquid in ethanol solution；
5, it takes the adhesive in appropriate step 2 to be added in step 1, pelletizes；
6, the spacer layer coating liquid of appropriate step 3 is taken to be coated；
7, the sustained release coating liquid of appropriate step 4 is taken to be coated.It is spare up to sustained release capsule core；
8,80mg is taken to be sustained capsule core, 34mg crosslinked polyvinylpyrrolidone, 6mg magnesium stearate and 80mg microcrystalline cellulose, mixing
Uniformly, use suitable water as adhesive, tabletting to obtain the final product.
Embodiment 2
The present embodiment prescription preparation step:
1, Enrofloxacin 100mg is weighed, carboxymethyl starch receives 60mg, and microcrystalline cellulose 160mg is uniformly mixed spare；
2, it takes appropriate polyvinylpyrrolidone to be dissolved in 75% ethanol solution, makes the mass fraction of polyvinylpyrrolidone
10%, it dissolves intact rear spare as adhesive；
3, hypromellose 12mg is taken, talcum powder 4mg is evenly spread in 10% ethanol solution of 100mg, as separation layer
Coating solution is spare；
4, ethyl cellulose 52mg, triethyl citrate 4mg are taken, titanium dioxide 4mg, 4mg polyethanol 6000 evenly spreads to 10%
It is spare as sustained release coating liquid in ethanol solution；
5, it takes the adhesive in appropriate step 2 to be added in step 1, pelletizes；
6, the spacer layer coating liquid of appropriate step 3 is taken to be coated；
7, the sustained release coating liquid of appropriate step 4 is taken to be coated.It is spare up to sustained release capsule core；
8,80mg is taken to be sustained capsule core, 34mg crosslinked polyvinylpyrrolidone, 6mg magnesium stearate and 80mg microcrystalline cellulose, mixing
Uniformly, use suitable water as adhesive, tabletting to obtain the final product.
Claims (6)
1. a kind of Enrofloxacin pellet tablet, it is characterised in that including following components and each component parts by weight are as follows: Enrofloxacin
100-300 parts, 10-40 parts of disintegrating agent, 20-60 parts of adhesive, 300-1000 parts of diluent；It is made after mixing raw material when preparation
Pellet particle is coated with separation layer in pellet particle surface, is coated with slow release layer again outside separation layer.
2. a kind of Enrofloxacin pellet tablet according to claim 1, it is characterized in that: the disintegrating agent is low-substituted hydroxypropyl first
Base cellulose, sodium carboxymethylcellulose, any one or more in sodium carboxymethyl starch.
3. a kind of Enrofloxacin pellet tablet according to claim 1, it is characterized in that: described adhesive is water, ethyl alcohol, poly- second
Alkene pyrrolidone, any one or more in starch slurry.
4. a kind of Enrofloxacin pellet tablet according to claim 1, it is characterized in that: the diluent is microcrystalline cellulose,
Starch, mannitol, dextrin, any one or more in sucrose.
5. a kind of Enrofloxacin pellet tablet according to claim 1, it is characterized in that: the separation layer is by adhesive 20-60
Part, 10-30 parts of antiplastering aid compositions；Wherein described adhesive is low viscosity hypromellose；The antiplastering aid is talcum powder
With any one in silica.
6. a kind of Enrofloxacin pellet tablet according to claim 1, it is characterized in that: the slow release layer is by slow-release material 100-
300 parts, 20-80 parts of plasticiser, 10-40 parts and pore-foaming agent 5-30 parts compositions of coatings auxiliary agent；The slow-release material includes methyl
Acrylic resin copolymer, polyacrylic resin, one or more of ethyl cellulose and cellulose acetate；The plasticiser
Including triethyl citrate；The coatings auxiliary agent is titanium dioxide；The pore-foaming agent is polyethylene glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710735932.4A CN109419777A (en) | 2017-08-24 | 2017-08-24 | A kind of Enrofloxacin pellet tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710735932.4A CN109419777A (en) | 2017-08-24 | 2017-08-24 | A kind of Enrofloxacin pellet tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109419777A true CN109419777A (en) | 2019-03-05 |
Family
ID=65500431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710735932.4A Pending CN109419777A (en) | 2017-08-24 | 2017-08-24 | A kind of Enrofloxacin pellet tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109419777A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110075082A (en) * | 2019-04-12 | 2019-08-02 | 瑞普（天津）生物药业有限公司 | A kind of Enrofloxacin fast release micropill and preparation method thereof |
-
2017
- 2017-08-24 CN CN201710735932.4A patent/CN109419777A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110075082A (en) * | 2019-04-12 | 2019-08-02 | 瑞普（天津）生物药业有限公司 | A kind of Enrofloxacin fast release micropill and preparation method thereof |
| CN110075082B (en) * | 2019-04-12 | 2021-05-18 | 瑞普（天津）生物药业有限公司 | Enrofloxacin quick-release pellet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU737121B2 (en) | Tramadol multiple unit formulations | |
| EP2386308B1 (en) | Site-specific intestinal delivery of adsorbents, alone of in combination with degrading molecules | |
| WO2022022369A1 (en) | Sustained-release formulation of tofacitinib or salt thereof and preparation method therefor | |
| CN101371845B (en) | Medicament composition for curing mouth ulcer | |
| EP3215132B1 (en) | Amantadine for improving gait in multiple sclerosis | |
| KR101156054B1 (en) | A stable and control-released pharmaceutical composition comprising eperisone | |
| CN105326837A (en) | Memantine hydrochloride sustained release-donepezil quick release compound capsule | |
| WO2021129735A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
| KR20120094882A (en) | Sustained-release pharmaceutical composition comprising mosapride or salt thereof | |
| JP2006528604A5 (en) | ||
| EP2481398A1 (en) | Slow-release cilostazol tablet having an improved elution rate and minimal side effects | |
| CN105520934B (en) | Application of michelia lactone dimethylamine | |
| EP3981390A1 (en) | Lacosamide pharmaceutical composition and pharmaceutical preparation thereof | |
| CN109419777A (en) | A kind of Enrofloxacin pellet tablet | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101084904B (en) | Cefixime sustained-release double-layer tablet | |
| WO2022007758A1 (en) | Brivaracetam pharmaceutical composition, preparation method therefor and application thereof | |
| JP2010511023A (en) | Memantine formulation | |
| CN103655506A (en) | Cefaclor sustained release tablet and preparation method thereof | |
| KR101761983B1 (en) | Fast dissolving oral thin film composite and preparing method thereof | |
| CN104856971A (en) | Pulse double-release preparation as well as preparation method and application thereof | |
| CN109069428A (en) | The preparation method of Mesalazine solid pharmaceutical preparation | |
| EP4072532B1 (en) | Dosage form for use in treating or preventing of a disease | |
| TWI835118B (en) | Brexpiprazole oral film inclusion complex, preparation method and use thereof | |
| CN102579394A (en) | Method for preparing xanthan gum olsalazine colon-specific sustained release tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190305 |